SunTrust Banks Inc. recorded Versartis Inc (NASDAQ:VSAR), boosting its price target to $25.00 earlier today
- Updated: December 1, 2016
Showing a price of $12.20, Versartis Inc (NASDAQ:VSAR) traded -2.01% lower on the day. With the last stock price close up 6.22% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same period. VSAR has recorded a 50-day average of $11.87 and a two hundred day average of $11.49. 96,679 shares of VSAR exchanged hands, down from an avg. volume of 185,481
SunTrust Banks Inc. increased the stock price target of Versartis Inc (NASDAQ:VSAR) to $25.00 indicating a possible upside of 1.05%.
Previously on 12/21/2015, Citigroup released a statement about Versartis Inc (NASDAQ:VSAR) bumped up the target price from $0.00 to $22.00 that suggested an upside of 0.95%.
See Chart Below
Versartis Inc has a 52 week low of $6.17 and a 52 week high of $14.69 The company’s market cap is currently $0.
General Company Details For Versartis Inc (NASDAQ:VSAR)
Versartis, Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company's product pipeline includes VRS-317 and XTEN Technology. The Company's VRS-317 combines the rhGH amino acid sequence utilized in approved rhGH products with a half-life extension technology, XTEN, to enable less frequent administration. The XTEN technology consists of hydrophilic amino acids added at the genetic level as part of the manufacturing process. The Company's XTEN is a recombinant polypeptide designed to extend the in vivo half-life of peptides and proteins in a tunable manner. The XTEN sequence consists of hydrophilic amino acids and possesses various additional properties, which are used for the development of protein pharmaceuticals.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.